Table 1 Comparison of demographic and clinical characteristics of included and excluded CRC patients
| Included patients (n = 433) |
Excluded patients (n = 70) | p-value* | |
|---|---|---|---|
| Mean age in years (SD) | 66.3 (9.5) | 69.4 (9.9) | 0.01† |
| Male | 61.2% | 68.6% | 0.24 |
| Mean BMI (SD)* | 26.3 (5.2) | 26.0 (3.8) | 0.55 |
| Comorbidities at time of enrollment into registry | |||
| Hypertension | 41.3% | 45.7% | 0.81 |
| Diabetes mellitus with end-organ damage | 0.7% | 2.9% | 0.27 |
| Diabetes mellitus without end-organ damage | 14.6% | 18.6% | 0.50 |
| Thyroid disease | 9.0% | 4.3% | 0.35 |
| Coronary heart disease | 8.3% | 8.6% | 1.00 |
| Tumor other than colorectal or lymphoma or leukemia | 7.9% | 7.1% | 1.00 |
| Chronic gastric or bowel disease | 6.7% | 1.4% | 0.18 |
| Adiposity | 6.5% | 2.9% | 0.44 |
| Chronic pulmonary disease | 5.8% | 4.3% | 0.90 |
| Anemia | 4.4% | 4.3% | 1.00 |
| Heart failure | 4.2% | 7.1% | 0.44 |
| Kidney disease | 3.5% | 8.5% | 0.15 |
| Urogenital disease | 3.2% | 5.7% | 0.07 |
| Cerebrovascular disease | 2.5% | 1.4% | 1.00 |
| Myocardial infarction | 2.5% | 0.0% | 0.47 |
| Peripheral artery occlusive disease | 2.1% | 1.4% | 1.00 |
| Mild liver disease | 1.4% | 0.0% | 1.00 |
| Moderate or severe liver disease | 0.7% | 0.0% | 1.00 |
| Polyneuropathy | 1.9% | 1.4% | 1.00 |
| Peptic ulcer disease | 0.5% | 0.0% | 1.00 |
| Connective tissue disease | 0.5% | 0.0% | 1.00 |
| Metastatic solid tumor other than colorectal | 0.5% | 0.0% | 1.00 |
| Hemiplegia | 0.2% | 0.0% | 1.00 |
| AIDS | 0.2% | 0.0% | 1.00 |
| Myocardial insufficiency | 0.0% | 0.0% | 1.00 |
| Dementia | 0.0% | 1.4% | 0.16 |
| Localization of primary tumor | 0.82 | ||
| Colon | 56.4% | 58.6% | – |
| Rectum | 43.4% | 41.4% | – |
| Inoperable primary tumor | 19.9% | 24.3% | 0.63 |
| Tumor stage (UICC) at primary diagnosis | 0.82 | ||
| I | 3.7% | 4.3% | – |
| II | 7.2% | 5.7% | – |
| III | 13.9% | 11.4% | – |
| IV | 66.5% | 72.9% | – |
| Progression prior to questioning | 0.27 | ||
| 0 | 75.3% | 75.7% | – |
| 1 | 16.6% | 12.9% | – |
| 2 or more | 4.4% | 7.1% | – |
| Metastases | |||
| Liver | 61.4% | 58.6% | 0.79 |
| Lung | 23.8% | 21.4% | 0.83 |
| Peritoneal | 14.6% | 20.0% | 0.49 |
| Bone | 3.0% | 2.9% | 0.93 |
| Number of metastatic localizations prior to questioning | < 0.01† | ||
| 0 | 10.9% | 7.1% | – |
| 1 | 51.2% | 55.7% | – |
| 2 | 24.9% | 27.1% | – |
| 3 or more | 7.6% | 5.7% | – |
| Treatment line at time of questioning | 0.93 | ||
| First-line palliative | 55.2% | 60.0% | – |
| Break after first-line | 23.3% | 20.0% | – |
| Second-line palliative or break after second-line | 15.5% | 14.3% | – |
| Third-line palliative or later | 5.1% | 5.7% | – |
| Most current chemotherapy at time of questioning | < 0.01† | ||
| Irinotecan-based | 44.8% | 44.3% | – |
| Oxaliplatin-based | 37.4% | 34.3% | – |
| Fluoropyrimidine monotherapy | 10.4% | 15.7% | – |
| Irinotecan plus oxaliplatin | 4.9% | 2.9% | – |
| Additional antibody treatment | 0.68 | ||
| None | 22.6% | 28.6% | – |
| VEGF | 49.7% | 42.9% | – |
| EGFR | 26.1% | 27.1% | – |
| RAS mutation status | 0.74 | ||
| Wild-type | 38.1% | 42.9% | – |
| Mutation | 40.9% | 40.0% | – |